MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)

PHASE3CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

October 23, 2020

Study Completion Date

October 23, 2020

Conditions
Alcohol Withdrawal Syndrome
Interventions
DRUG

Magnesium

Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).

DRUG

Placebo Oral Tablet

Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.

Trial Locations (11)

75014

Clinique des maladies mentales et de l'encéphale, Paris

75015

Hôpital Européen Georges Pompidou-Service de chirugie orthopédique, AP-HP, Paris

Hôpital Européen Georges Pompidou-Service de médecine interne, AP-HP, Paris

Hôpital européen Georges-Pompidou-Service hépato-gastroentérologie, Paris

78322

Institut MGEN de la Verriere, Le Mesnil-Saint-Denis

Institut MGEN la Verriere-service SSR addictologie, Le Mesnil-Saint-Denis

92130

Hôpital Corentin Celton, AP-HP, Issy-les-Moulineaux

92310

Centre Hospitalier des quatre villes, Sèvres

92700

Hôpital Louis Mourier, AP-HP, Colombes

93800

Clinique des Platanes, Épinay-sur-Seine

Unknown

Hôpital Emile ROUX, Limeil-Brévannes

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03033823 - MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA) | Biotech Hunter | Biotech Hunter